CoChat

Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer

Open access
Huang, Mengqiu, Chen, Lin, Ma, Xiaoyan, Xu, Houqiang · 2024 · Cancer Cell International

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 20 of the 33 sources its claims cite were checked for support.

Abstract

BACKGROUND: Prostate cancer (PCa) is a leading malignancy among men globally, with rising incidence rates emphasizing the critical need for better detection and therapeutic approaches. The roles of HSP90AB1 and PARP1 in prostate cancer cells suggest potential targets for enhancing treatment efficacy. METHODS: This study investigated the overexpression of HSP90AB1 and PARP1 in prostate cancer cells and the impact of HSP90AB1 knockdown on the sensitivity of these cells to the PARP inhibitor olaparib. We also explored the combined effect of olaparib and celastrol, an HSP90 inhibitor, on the clonogenic survival, migration, proliferation, and overall viability of prostate cancer cells, alongside the modulation of the PI3K/AKT pathway. An in vivo PC3 xenograft mouse model was used to assess the antitumor effects of the combined treatment. RESULTS: Our findings revealed significant overexpression of HSP90AB1 and PARP1 in prostate cancer cells. Knockdown of HSP90AB1 increased cell sensitivity to olaparib. The combination of olaparib and celastrol significantly reduced prostate cancer cell survival, migration, proliferation, and enhanced cumulative DNA damage. Celastrol also downregulated the PI3K/AKT pathway, increasing cell susceptibility to olaparib. In vivo experiments demonstrated that celastrol and olaparib together exerted strong antitumor effects. CONCLUSIONS: The study indicates that targeting both HSP90AB1 and PARP1 presents a promising therapeutic strategy for prostate cancer. The synergistic combination of celastrol and olaparib enhances the efficacy of treatment against prostate cancer, offering a potent approach to combat this disease.

Overview

CoChat Summary

TL;DR

Celastrol, an HSP90 inhibitor, combined with olaparib reduced prostate cancer cell clonogenicity, migration, proliferation, and viability while increasing DNA damage and downregulating PI3K/AKT. In PC3 xenografts, the combination reduced tumor weight and volume and Ki-67, suggesting a potential therapeutic strategy for prostate cancer.

Key findings

  • HSP90AB1 and PARP1 were overexpressed in prostate cancer cell lines versus normal RWPE-1 cells and in TCGA PRAD tumor samples; high expression of either was associated with diminished overall survival in PCa patients.
  • HSP90AB1 knockdown significantly enhanced sensitivity of 22RV1, PC3, and DU145 cells to olaparib at 20, 40, 60, and 80 µM.
  • Celastrol (1 µM) plus olaparib (50 µM) more effectively reduced clonogenic survival, migration, proliferation, and viability than monotherapy, and increased γH2AX foci and comet tail moment, with downregulation of phosphorylated PI3K and AKT.
  • In PC3 xenografts, celastrol (2 mg/kg) plus olaparib (30 mg/kg) given intraperitoneally thrice weekly for 3 weeks significantly reduced tumor weight (P < 0.001), tumor volume (P < 0.01), and Ki-67 expression (P < 0.01); major organ weights did not show appreciable changes.

Methods

  • In vitro studies used RWPE-1, 22RV1, PC3, and DU145 cells; TCGA, R2, and GEPIA databases; HSP90AB1 shRNA knockdown; and assays including western blot, CCK-8, colony formation, wound scratch, EdU, immunofluorescence, immunohistochemistry, and alkaline comet assay.
  • In vivo studies used male BALB/c nude mice, 5–6 weeks old, with subcutaneous PC3 xenografts; mice were randomized into groups of 6 and treated with DMSO, celastrol, olaparib, or combination, with tumor volume calculated as (length × width²)/2.
  • Statistical analysis used mean ± SD from at least three experiments, Student’s two-tailed t-test, one-way ANOVA, GraphPad Prism 8.0, and significance at P < 0.05.

Limitations

  • Stated in the paper: 22RV1 cells were not used in subsequent phenotypic experiments because they had difficulty forming a monolayer, which could affect experimental outcomes.
  • Evident from the text: the paper does not include a formal limitations section; in vivo efficacy was tested only in a PC3 xenograft model with 6 mice per group, without survival endpoints or clinical validation.
  • Evident from the text: toxicity assessment relied on body weight and major organ weights, without detailed histopathological or systemic toxicity analyses.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12935-024-03542-8

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 HSP90AB1 and PARP1 expression is elevated in PCa, and HSP90AB1 silencing increases olaparib sensitivity in PCa cell lines. (a) Differential expression of HSP90AB1 across various cancer types as compared to normal tissue samples in the Cancer Genome Atlas (TCGA) Database. (b) The transcript levels of the HSP90AB1 in PRAD were acquired from the TCGA database. (c) Elevated HSP90AB1 expression correlated with a diminished overall survival probability among patients with PCa. (d) Expression of PARP1 in various cancers versus normal tissues from TCGA. (e) The transcript levels of the PARP1 in PRAD were acquired from the TCGA database. (f) High expression of PARP1 was associated with poor overall survival probability in PCa patients. (g) Western blot analysis of HSP90AB1 and PARP1 protein levels in PCa cell lines. (h) Correlation of HSP90AB1 and PARP1 gene expression in PCa samples. The dataset came from GEPIA (http://gepia.cancer-pku.cn/). (i) Knockdown efficiency of HSP90AB1 in PCa cell lines. (j-l) Sensitivity of PCa cell lines to different concentration of olaparib (20, 40, 60, 80 µM) following HSP90AB1 knockdown. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 1 HSP90AB1 and PARP1 expression is elevated in PCa, and HSP90AB1 silencing increases olaparib sensitivity in PCa cell lines. (a) Differential expression of HSP90AB1 across various cancer types as compared to normal tissue samples in the Cancer Genome Atlas (TCGA) Database. (b) The transcript levels of the HSP90AB1 in PRAD were acquired from the TCGA database. (c) Elevated HSP90AB1 expression correlated with a diminished overall survival probability among patients with PCa. (d) Expression of PARP1 in various cancers versus normal tissues from TCGA. (e) The transcript levels of the PARP1 in PRAD were acquired from the TCGA database. (f) High expression of PARP1 was associated with poor overall survival probability in PCa patients. (g) Western blot analysis of HSP90AB1 and PARP1 protein levels in PCa cell lines. (h) Correlation of HSP90AB1 and PARP1 gene expression in PCa samples. The dataset came from GEPIA (http://gepia.cancer-pku.cn/). (i) Knockdown efficiency of HSP90AB1 in PCa cell lines. (j-l) Sensitivity of PCa cell lines to different concentration of olaparib (20, 40, 60, 80 µM) following HSP90AB1 knockdown. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)CC BY-NC-ND · PubMed Central
Fig. 2 The olaparib-celastrol combination more effectively impairs clonogenicity, migration, and growth of PCa cells. (a Colony formation assay of 22RV1, PC3, and DU145 cell lines following treatment with celastrol (1 µM) and olaparib (50 µM) or monotherapy, or DMSO. (b-c) Wound scratch assay of PC3 and DU145 cell lines treated with celastrol (1 µM) and olaparib (50 µM) or monotherapy, or DMSO. Scale bars: 500 μm. (d-e) Evaluation of proliferation and viability in PC3 and DU145 cell lines subjected to treatments with DMSO, celastrol (1 µM), olaparib (50 µM), and their combination through EdU and CCK-8 assays. Scale bars: 50 μm. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 2 The olaparib-celastrol combination more effectively impairs clonogenicity, migration, and growth of PCa cells. (a Colony formation assay of 22RV1, PC3, and DU145 cell lines following treatment with celastrol (1 µM) and olaparib (50 µM) or monotherapy, or DMSO. (b-c) Wound scratch assay of PC3 and DU145 cell lines treated with celastrol (1 µM) and olaparib (50 µM) or monotherapy, or DMSO. Scale bars: 500 μm. (d-e) Evaluation of proliferation and viability in PC3 and DU145 cell lines subjected to treatments with DMSO, celastrol (1 µM), olaparib (50 µM), and their combination through EdU and CCK-8 assays. Scale bars: 50 μm. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)CC BY-NC-ND · PubMed Central
Fig. 3 Olaparib and celastrol enhanced total DNA damage in PCa cells. (a, b) IF staining and western blot demonstrated γH2AX expression in PCa cells following a 48 h treatment with celastrol (1 µM) and olaparib (50 µM), celastrol or olaparib monotherapy, or DMSO. Scale bars: 25 μm. (c) Comet assay of PC3 cells treated with celastrol (1 µM) and olaparib (50 µM), either agent alone, or DMSO, for 48 h. The olive tail moment served as the metric for analysis and underwent statistical evaluation. Scale bars: 20 μm. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 3 Olaparib and celastrol enhanced total DNA damage in PCa cells. (a, b) IF staining and western blot demonstrated γH2AX expression in PCa cells following a 48 h treatment with celastrol (1 µM) and olaparib (50 µM), celastrol or olaparib monotherapy, or DMSO. Scale bars: 25 μm. (c) Comet assay of PC3 cells treated with celastrol (1 µM) and olaparib (50 µM), either agent alone, or DMSO, for 48 h. The olive tail moment served as the metric for analysis and underwent statistical evaluation. Scale bars: 20 μm. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)CC BY-NC-ND · PubMed Central
Fig. 4 Celastrol downregulates PI3K/AKT pathway and enhances sensitivity to olaparib. Western blot analysis of PI3K/AKT pathway modulation in PC3, DU145 and 22RV1 cells treated with celastrol (1 µM) and olaparib (50 µM), either agent alone, or DMSO, for 48 h. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 4 Celastrol downregulates PI3K/AKT pathway and enhances sensitivity to olaparib. Western blot analysis of PI3K/AKT pathway modulation in PC3, DU145 and 22RV1 cells treated with celastrol (1 µM) and olaparib (50 µM), either agent alone, or DMSO, for 48 h. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)CC BY-NC-ND · PubMed Central
Fig. 5 Cleastrol combined with olaparib exhibits an enhanced anti-tumor effect in PC3 xenografts in vivo. (a) Representative images of PCa tumor xenografts from each mouse (n = 6/group). (b, c) The weight and volume of tumors from each experimental group were documented and subjected to analysis. (d) Body weight percent change in mice bearing PCa xenografts over 26 days. (e, f) The weights of principle organs were measured and analyzed after sacrifice. (g) IHC for Ki-67 was conducted on tumor tissue and quantified using Image software. Scale bars: 100 μm. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 5 Cleastrol combined with olaparib exhibits an enhanced anti-tumor effect in PC3 xenografts in vivo. (a) Representative images of PCa tumor xenografts from each mouse (n = 6/group). (b, c) The weight and volume of tumors from each experimental group were documented and subjected to analysis. (d) Body weight percent change in mice bearing PCa xenografts over 26 days. (e, f) The weights of principle organs were measured and analyzed after sacrifice. (g) IHC for Ki-67 was conducted on tumor tissue and quantified using Image software. Scale bars: 100 μm. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 6 Not checked · 50 Own results and interpretations

39 more claims

Create a free account to see all 69 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 10

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 44 references

Cited by

See all 9

Metadata

Authors
Huang, M., Chen, L., Ma, X., & Xu, H.
Affiliations
  • Guiyang University (CN)
  • Guizhou Institute of Technology (CN)
  • Guizhou University (CN)
Corresponding author
Xu, Houqiang
Venue
Cancer Cell International
Published
2024-10-26
Volume
24
Issue
1
Pages
352-352
ISSN
1475-2867 (ISSN-L)
OpenAlex
W4403784131
Cited by
9
References
42
Citations by year
2026: 4 · 2025: 5
FWCI
2.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Cell International (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Zunyi City Science and Technology Plan Project (Zun City Science and Technology Cooperation HZ No. (2023) 248)
  • National Natural Science Foundation of China (31860242)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
prostate cancer, celastrol, olaparib, HSP90AB1, PARP1, PARP inhibitors, Hsp90 inhibitors, combination therapy, cell invasion, cell migration, PI3K/Akt signaling, DNA damage, tumor xenografts, synergistic antitumor effect

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer. https://app.cochat.ai/papers/10.1186/s12935-024-03542-8
The paper
Huang, M., Chen, L., Ma, X., & Xu, H. (2024). Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer. Cancer Cell International. https://doi.org/10.1186/s12935-024-03542-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.